PRICE T ROWE ASSOCIATES INC /MD/ - PUMA BIOTECHNOLOGY INC ownership

PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 103 filers reported holding PUMA BIOTECHNOLOGY INC in Q4 2021. The put-call ratio across all filers is 0.85 and the average weighting 0.0%.

Quarter-by-quarter ownership
PRICE T ROWE ASSOCIATES INC /MD/ ownership history of PUMA BIOTECHNOLOGY INC
ValueSharesWeighting
Q3 2022$108,000
-16.3%
45,4000.0%0.00%
Q2 2022$129,000
-7.2%
45,400
-5.9%
0.00%
Q1 2022$139,000
+215.9%
48,268
+235.9%
0.00%
Q4 2021$44,000
-57.3%
14,368
-2.0%
0.00%
Q3 2021$103,000
-23.7%
14,6680.0%0.00%
Q2 2021$135,000
-0.7%
14,668
+4.6%
0.00%
Q1 2021$136,000
-5.6%
14,025
-0.1%
0.00%
Q4 2020$144,000
-98.5%
14,041
-98.4%
0.00%
-100.0%
Q2 2020$9,443,000
+8.0%
905,357
-12.6%
0.00%0.0%
Q1 2020$8,741,000
+45.6%
1,035,611
+50.9%
0.00%0.0%
Q4 2019$6,005,000
-3.8%
686,306
+18.3%
0.00%0.0%
Q3 2019$6,243,000
-1.5%
579,971
+16.3%
0.00%0.0%
Q2 2019$6,337,000
-79.2%
498,609
-36.6%
0.00%
-75.0%
Q1 2019$30,488,000
+11998.4%
785,965
+18341.2%
0.00%
Q2 2018$252,000
-11.3%
4,262
+2.0%
0.00%
Q1 2018$284,000
-99.9%
4,179
-99.8%
0.00%
-100.0%
Q4 2017$195,379,000
-69.0%
1,976,517
-62.4%
0.03%
-70.4%
Q3 2017$629,474,000
+109.8%
5,256,567
+53.1%
0.11%
+100.0%
Q2 2017$300,103,000
+602.1%
3,433,672
+198.9%
0.05%
+575.0%
Q1 2017$42,741,000
+105.2%
1,148,945
+69.4%
0.01%
+100.0%
Q4 2016$20,828,000
-66.7%
678,435
-27.2%
0.00%
-69.2%
Q3 2016$62,455,000
+106.2%
931,474
-8.4%
0.01%
+116.7%
Q2 2016$30,293,000
-39.5%
1,016,874
-40.4%
0.01%
-45.5%
Q1 2016$50,112,000
-62.8%
1,706,222
-0.8%
0.01%
-60.7%
Q4 2015$134,818,000
+3.4%
1,719,612
-0.6%
0.03%
-3.4%
Q3 2015$130,426,000
-46.7%
1,730,703
-17.4%
0.03%
-42.0%
Q2 2015$244,527,000
-65.5%
2,094,447
-30.1%
0.05%
-65.8%
Q1 2015$707,879,000
+35.2%
2,998,090
+8.4%
0.15%
+31.5%
Q4 2014$523,653,000
-38.0%
2,766,701
-21.8%
0.11%
-39.7%
Q3 2014$844,400,000
+298.5%
3,539,423
+10.2%
0.18%
+300.0%
Q2 2014$211,884,000
-31.2%
3,210,367
+8.6%
0.05%
-33.3%
Q1 2014$307,760,000
-49.6%
2,955,248
-49.9%
0.07%
-1.4%
Q4 2013$610,108,000
+738.7%
5,893,048
+334.7%
0.07%
+288.9%
Q3 2013$72,742,000
-40.5%
1,355,606
-50.8%
0.02%
+12.5%
Q2 2013$122,334,0002,757,1340.02%
Other shareholders
PUMA BIOTECHNOLOGY INC shareholders Q4 2021
NameSharesValueWeighting ↓
GREAT POINT PARTNERS LLC 1,300,000$12,636,0002.61%
AIGH Capital Management LLC 964,590$9,376,0001.97%
Worth Venture Partners, LLC 226,758$2,204,0001.07%
Camber Capital Management LP 2,555,000$24,835,0000.85%
Palo Alto Investors LP 1,392,997$13,540,0000.77%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 3,769,795$36,642,0000.77%
GLOBEFLEX CAPITAL L P 428,680$4,167,0000.76%
Zebra Capital Management LLC 34,243$333,0000.37%
Sofinnova Investments, Inc. 344,917$3,353,0000.20%
RICE HALL JAMES & ASSOCIATES, LLC 605,792$5,888,0000.19%
View complete list of PUMA BIOTECHNOLOGY INC shareholders